Biocon Ltd - Share Price
BIOCON
Biocon LtdFinancials
Biocon LtdNews & Updates
Biocon stock surges 3% after Q3 PAT rises by 11% yoy to Rs187cr as robust growth seen across segment
Jan 21,2022 12:08 PM
The company's revenue from operations stood at Rs2,174cr in Q3FY22 increasing by a whopping 17% from Rs1,857cr of the December qua
Meeting Type
Meeting Date
| Resolution Type | Description Of Resolution | IiAS Recommendation |
|---|
Peer Comparison
| Name | LTP | PE | Mar Cap | NP Qtr | Div. Yld | Sales Qtr | BV |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | 808.05 | 108.47 | 193,626.33 | 809.07 | 0.93 | 4,120.93 | 113.47 |
| Divis Laboratories Ltd | 4,049.20 | 51.01 | 107,513.45 | 606.39 | 0.49 | 1,967.86 | 372.89 |
| Dr Reddys Laboratories Ltd | 4,402.85 | 45.34 | 73,340.01 | 449.00 | 0.57 | 3,809.50 | 1,049.62 |
| Cipla Ltd | 905.65 | 27.15 | 72,943.78 | 730.83 | 0.55 | 3,870.56 | 261.90 |
| Piramal Enterprises Ltd | 2,358.55 | 219.78 | 56,282.87 | 34.34 | 1.32 | 515.35 | 962.90 |
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Biocon LtdSummary & Reports
Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. Some of its key brands are INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab), KRABEVAA (Bevacizumab) and ALZUMAb (Itolizumab), a first in class anti-CD6 monoclonal antibody. The company has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, ... More
Registered Office
20th KM Hosur Road Hebbagodi,Electronic City P O,Bangalore, Karnataka,560100
Tell. : +91-80-28082808
Website : http://www.biocon.com
Email : co.secretary@biocon.com
Registrar Office
Karvy Selenium Tow-B, Nanakramguda, Hyderabad-500032 INDIA
Tell. : +91-40-67162222
Website : www.kfintech.com
Email : einward.ris@kfintech.com
Reports by biocon-ltd-share-price
Latest Release by biocon-ltd-share-price
Result Express
Biocon Ltd's Q3FY19 consolidated net profit rises 136.34% yoy to Rs217.20cr : Beats Estimates
Jan 27, 2022 05:16 AM
The company’s consolidated revenue stood at Rs1,540.80cr, up 45.65% yoy and 16.64% qoq.
Shareholding Snapshot
Loading ...
| Dec - 2021 | |
|---|---|
| Promoter | - |
| Foreign | 20.91% |
| Indian | 39.73% |
| Total Promoter | 60.64% |
| Non Promoter | - |
| Institutions | 23.37% |
| Non-Institutions | 15.34% |
| Total Non-Promoter | 38.71% |
| Custodian | 0.65% |
| Total | 100% |
Corporate Action
Purpose
Board Meeting
Exp. Date
20 Jan 2022
Annc. Date
03 Jan 2022
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled o... More
Purpose
Board Meeting
Exp. Date
03 Jan 2022
Annc. Date
03 Jan 2022
This is in continuation to our intimation dated September 16, 2021, with regard to merger of Covidsh... More
Purpose
Board Meeting
Exp. Date
21 Oct 2021
Annc. Date
05 Oct 2021
Quarterly ResultsPursuant to Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Require... More
